179 related articles for article (PubMed ID: 25806320)
21. First-Generation Epidermal Growth Factor Receptor Inhibitors Plus Antiangiogenic Drugs Versus Third-Generation Epidermal Growth Factor Receptor Inhibitors in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis.
Mosca M; Conci N; Di Federico A; Tateo V; Favorito V; Zappi A; Gelsomino F; De Giglio A
JCO Precis Oncol; 2023 May; 7():e2300073. PubMed ID: 37262392
[TBL] [Abstract][Full Text] [Related]
22. Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence.
Lu S; Shih JY; Jang TW; Liam CK; Yu Y
Adv Ther; 2021 May; 38(5):2038-2053. PubMed ID: 33730350
[TBL] [Abstract][Full Text] [Related]
23. Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence.
Wang X; Goldstein D; Crowe PJ; Yang JL
Onco Targets Ther; 2016; 9():5461-73. PubMed ID: 27660463
[TBL] [Abstract][Full Text] [Related]
24. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
Tan CS; Cho BC; Soo RA
Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
[TBL] [Abstract][Full Text] [Related]
25. Optimal sequence of LT for symptomatic BM in EGFR-mutant NSCLC: a comparative study of first-line EGFR-TKIs with/without upfront LT.
Niu L; Wu H; Gao R; Chen L; Wang J; Duan H; Long Y; Xie Y; Zhou Q; Zhou R
J Cancer Res Clin Oncol; 2024 Feb; 150(2):94. PubMed ID: 38369644
[TBL] [Abstract][Full Text] [Related]
26. Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors.
Yonesaka K; Iwama E; Hayashi H; Suzuki S; Kato R; Watanabe S; Takahama T; Tanizaki J; Tanaka K; Takeda M; Sakai K; Azuma K; Chiba Y; Atagi S; Nishio K; Okamoto I; Nakagawa K
Sci Rep; 2019 Dec; 9(1):19501. PubMed ID: 31862929
[TBL] [Abstract][Full Text] [Related]
27. Clinical management of third-generation EGFR inhibitor-resistant patients with advanced non-small cell lung cancer: Current status and future perspectives.
Zhang YC; Zhou Q; Wu YL
Cancer Lett; 2019 Sep; 459():240-247. PubMed ID: 31201840
[TBL] [Abstract][Full Text] [Related]
28. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
[TBL] [Abstract][Full Text] [Related]
29. [Survival analysis of different kinds of tyrosine kinase inhibitors in the treatment of patients with epidermal growth factor receptor mutated non-small cell lung cancer and leptomeningeal metastasis].
Xu HY; Chen HQ; Kong JX; Zhang Y; Liu S; Yang GJ; Wang Y
Zhonghua Yi Xue Za Zhi; 2022 Feb; 102(6):399-405. PubMed ID: 35144338
[No Abstract] [Full Text] [Related]
30. The prospect of combination therapies with the third-generation EGFR-TKIs to overcome the resistance in NSCLC.
Li S; Zhu S; Wei H; Zhu P; Jiao Y; Yi M; Gong J; Zheng K; Zhang L
Biomed Pharmacother; 2022 Dec; 156():113959. PubMed ID: 36411663
[TBL] [Abstract][Full Text] [Related]
31. Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling.
Yu D; Zhao W; Vallega KA; Sun SY
Lung Cancer (Auckl); 2021; 12():1-10. PubMed ID: 33574724
[TBL] [Abstract][Full Text] [Related]
32. Comparing EGFR tyrosine kinase inhibitor treatments in EGFR-mutated non-small cell lung cancer across Asian and non-Asian patients: a plain language summary.
Kim E
Future Oncol; 2022 Feb; 18(4):417-424. PubMed ID: 34918542
[TBL] [Abstract][Full Text] [Related]
33. Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer.
Takahashi A; Seike M; Chiba M; Takahashi S; Nakamichi S; Matsumoto M; Takeuchi S; Minegishi Y; Noro R; Kunugi S; Kubota K; Gemma A
Sci Rep; 2018 Oct; 8(1):14896. PubMed ID: 30291293
[TBL] [Abstract][Full Text] [Related]
34. Hype or hope - Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC?
Papini F; Sundaresan J; Leonetti A; Tiseo M; Rolfo C; Peters GJ; Giovannetti E
Crit Rev Oncol Hematol; 2021 Oct; 166():103454. PubMed ID: 34455092
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of re-challenging 160 mg furmonertinib for advanced NSCLC after resistance to third-generation EGFR-TKIs targeted agents: A real-world study.
Qi R; Fu X; Yu Y; Xu H; Shen M; He S; Lv D
Lung Cancer; 2023 Oct; 184():107346. PubMed ID: 37604026
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness comparison of third-generation EGFR-TKI as initial and sequential therapy in adjuvant treatment for EGFR mutation-sensitive stage IIIA non-small cell lung cancer after surgery.
Ma W; Sheng Z; Niu Y; Yan B; Chen Y; Yang H; Li R
Heliyon; 2023 Nov; 9(11):e20955. PubMed ID: 37920491
[TBL] [Abstract][Full Text] [Related]
37. Brain metastases in resected non-small cell lung cancer: The impact of different tyrosine kinase inhibitors.
Yun PJ; Wang GC; Chen YY; Wu TH; Huang HK; Lee SC; Chang H; Huang TW
PLoS One; 2019; 14(5):e0215923. PubMed ID: 31048854
[TBL] [Abstract][Full Text] [Related]
38. The peripheral blood neutrophil-to-lymphocyte ratio is a prognostic predictor for survival of EGFR-mutant nonsmall cell lung cancer patients treated with EGFR-TKIs.
Zhang Y; Feng YC; Zhu HG; Xiong TC; Hou YS; Song J; Jiang W; Zhu CJ
Medicine (Baltimore); 2018 Jul; 97(30):e11648. PubMed ID: 30045314
[TBL] [Abstract][Full Text] [Related]
39. Dynamic cfDNA Analysis by NGS in
Ma L; Li H; Wang D; Hu Y; Yu M; Zhang Q; Qin N; Zhang X; Li X; Zhang H; Wu Y; Lv J; Yang X; Yu R; Zhang S; Wang J
Front Oncol; 2021; 11():643199. PubMed ID: 33842353
[TBL] [Abstract][Full Text] [Related]
40. Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases.
Zhang G; Cheng R; Zhang Z; Jiang T; Ren S; Ma Z; Zhao S; Zhou C; Zhang J
Sci Rep; 2017 Feb; 7():42979. PubMed ID: 28211502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
